It’s time to let scientists study whether LSD, marijuana and ecstasy can ease psychiatric disorders
Discovery of new psychiatric medication, whether for the treatment of depression, autism or schizophrenia, is at a virtual standstill. As just one example, the antidepressants on the market today are no more effective at reversing the mood disorder than those that first became available in the 1950s.
New thinking is desperately needed to aid the estimated 14 million American adults who suffer from severe mental illness. Innovation would likely accelerate if pharmacologists did not have to confront an antiquated legal framework that, in effect, declares off-limits a set of familiar compounds that could potentially serve as the chemical basis for entire new classes of drugs.
LSD, ecstasy (MDMA), psilocybin and marijuana have, for decades, been designated as drugs of abuse. But they had their origins in the medical pharmacopeia. Through the mid-1960s, more than 1,000 scientific publications chronicled the ways that LSD could be used as an aid to make psychotherapy more effective. Similarly, MDMA began to be used as a complement to talk therapy in the 1970s. Marijuana has logged thousands of years as a medicament for diseases and conditions ranging from malaria to rheumatism.
National laws and international conventions put a stop to all that. The Controlled Substances Act of 1970 declared that these drugs have “no currently accepted medical use” and classified them in the most stringently regulated category of controlled substances: Schedule I. The resulting restrictions create a de facto ban on their use in both laboratories and clinical trials, setting up a catch-22: these drugs are banned because they have no accepted medical use, but researchers cannot explore their therapeutic potential because they are banned. Three United Nations treaties extend similar restrictions to much of the rest of the world.
The decades-long research hiatus has taken its toll. Psychologists would like to know whether MDMA can help with intractable post-traumatic stress disorder, whether LSD or psilocybin can provide relief for cluster headaches or obsessive-compulsive disorder, and whether the particular docking receptors on brain cells that many psychedelics latch onto are critical sites for regulating conscious states that go awry in schizophrenia and depression.
The Latest on: Psychoactive Drug Research
via Google News
The Latest on: Psychoactive Drug Research
- Reforming cannabis laws is a complex challenge, but New Zealand’s history of drug reform holds important lessonson June 28, 2020 at 10:23 pm
New Zealand will hold the world’s first national referendum on legalising recreational use of cannabis in September. It must learn from mistakes in implementing earlier drug law reforms.
- Therapeutic Drug Monitoring Market Size to Surpass US$ 1227.9 million by 2025on June 28, 2020 at 9:43 pm
The global Therapeutic Drug Monitoring market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 3.2% in the forecast period of 2020 to 2025 and will ...
- Shock treatment, exorcism, psychotropic drugs: behind ‘conversion therapy’ for queerson June 27, 2020 at 3:30 am
As the recent death of Anjana Harish revealed, the dangerous practice of ‘conversion therapy’ for queer people is still going strong. This Pride Month, a new UN report urges governments to ban it ...
- RIP Lester Grinspoon, Who Encouraged Americans To Reconsider Demonized Drugson June 26, 2020 at 3:45 pm
For half a century, Grinspoon tirelessly advocated a more rational and tolerant approach to marijuana and other psychoactive substances.
- 5 Things CBD Can Do For Youon June 25, 2020 at 5:00 pm
Horticulturists have bred strains with high proportions of THC (Skunk) for maximum psychoactive effect and high ... CBD is calming without producing a sense of being drug-affected or intoxicated. Some ...
- Non-medical use of prescription drugs among skilled workers: a pilot study in Nigeriaon June 25, 2020 at 5:57 am
More than ever, the world is facing a challenge of non-medical use of prescription drugs among people of all ages, genders and occupations. Evidence shows that pharmaceutical opioids (tramadol, ...
- Rise in CBD and CBG's Popularity Driven By Combination of Non-psychoactive Nature and Therapeutic Propertieson June 23, 2020 at 6:19 am
THC adoption is being boosted by its use in the recreational market, while CBD, thanks to its non-psychoactive nature, is quickly making its way into everything from medicines to edibles to pet food, ...
- East African legislators back bid to provide medical assistance to drug addictson June 22, 2020 at 8:26 am
This is according to Harm Reduction International (HRI), a leading non-governmental organisation working to reduce the negative health, social and human rights impacts of drug use and drug policy by ...
- The World Health Organization Removed Cannabis from the 'Drug' Categoryon June 21, 2020 at 9:54 pm
The debate on the subject of whether Cannabis should still be on the list of drugs has been brought to a new phase, when the World Health Organization (WHO), in its last general balance, eliminated ...
- Wastewater tests reveal ‘bath salts’ amid designer drug trendon June 18, 2020 at 3:30 am
Wastewater analysis reveals disturbing trends in designer drug use across Australia, including the emergence of new psychoactive substances commonly known as “bath salts”.
via Bing News